<DOC>
	<DOCNO>NCT00872599</DOCNO>
	<brief_summary>The hypothesis test see drug fenofibrate increase important chemical body specifically kidney , help rid body salt kidney , decrease blood pressure improve insulin sensitivity high-salt intake individual hypertension .</brief_summary>
	<brief_title>The Effect Peroxisome Proliferator-activated Receptor ( PPAR ) Alpha Agonist Cytochrome P450 ( CYP ) Monooxygenase Activity Humans</brief_title>
	<detailed_description>Hypertension affect 73 million people United States billion people worldwide contribute death due stroke , myocardial infarction , end-stage kidney disease congestive heart failure . Fifty 60 % individual hypertension `` salt-sensitive '' hypertension , characterize exaggerated blood pressure response increase salt intake . Salt-sensitive hypertension associate increased mortality due cardiovascular disease . This study test hypothesis administration PPARa agonist , intervention increase renal tubular Cyp2c 4a expression rodent , increase urinary excretion 20-hydroxyeicosatetraenoic acid ( HETE ) epoxyeicosatrienoic acid ( EET ) , induce natriuresis , decrease blood pressure , improve insulin sensitivity high-salt intake individual hypertension . Metabolites P450 arachidonic acid monooxygenases play important role regulation blood pressure rodent model . Targeted disruption murine Cyp4a gene provide insight role renal monooxygenases epoxygenases regulation salt excretion blood pressure . PPARa agonists induce expression renal tubular monoxygenases epoxygenases decrease blood pressure Ang II- dependent salt-sensitive rodent model hypertension . PPARa agonists report reduce blood pressure clinical trial human . The effect PPARa agonist renal vasodilation , sodium excretion excretion urinary epoxygenase monooxygenase product response salt load know . The regulation urinary 20-HETE excretion may impair human hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Ambulatory subject , 1870 year age , inclusive For female subject , follow condition must meet Postmenopausal status least 1 year , Status post surgical sterilization , If childbearing potential , utilization adequate birth control willingness undergo urine betahcg test prior drug treatment every study day Secondary cause hypertension Diabetes type 1 type 2 define fast glucose 126 mg/dl great use antidiabetic medication Use hormone replacement therapy Statin fibrate therapy A seat systolic blood pressure ( SBP ) great 179 mmHg seat diastolic blood pressure ( DBP ) great 110 mmHg Pregnancy Breastfeeding Cardiovascular disease history myocardial infarction , presence angina pectoris , significant arrhythmia , congestive heart failure , ( LV hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second third degree heart block , mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy Treatment anticoagulant History serious neurologic disease cerebral hemorrhage , stroke , transient ischemic attack History presence immunological hematological disorder Diagnosis asthma Clinically significant gastrointestinal impairment could interfere drug absorption Impaired hepatic function ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 2.0 x upper range ) Known preexist gallbladder disease Impaired renal function ( eGFR &lt; 60 ml/min/1.73M2 ) Hematocrit &lt; 35 % Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult Treatment glucocorticoid therapy Treatment lithium salt History alcohol drug abuse Treatment investigational drug 1 month precede study Mental condition render subject unable understand nature , scope possible consequence study Inability comply protocol , e.g uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Phenotyping</keyword>
	<keyword>High Salt intake</keyword>
	<keyword>frequently sample IV glucose tolerance test ( FSIVGTT )</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>epoxyeicosatrienoic acid</keyword>
	<keyword>hydroxyeicosatetraenoic acid</keyword>
	<keyword>dihydroxyeicosatrienoic acid</keyword>
	<keyword>PPAR Alpha Agonist</keyword>
	<keyword>CYP Monooxygenase Activity</keyword>
</DOC>